# FFF: Complete Description of Coupled Transport and Biomolecular Interactions

$\underline{N}_{i} = -\underline{D}_{i} \nabla c_{i} + \frac{\underline{z}_{i}}{ \underline{z}_{i} } u_{i} c_{i} \underline{E} + $	Ci Uni Kallarei	V.EE=Pe=Sz;Fc;
dei - TNI P		( <u>E</u> = - ∇ <u>Φ</u> )
Ot = - V. M. + Nui	E.P/E.O.	$\nabla \cdot \underline{J} = - \frac{\partial P_e}{\partial t}$
Diffusion-	TIOS S.P.	$J = \leq z_i F \underline{N}_i$
Reaction	(W) add	"E.Q.S."
$\int \frac{p p y}{Dt} =$	-Vp + uV + pE+	+ P. VE) + tother
Stokes $\nabla \cdot \underline{v} = 0$	(incomp.fluid)	
(where D	$\frac{1}{t} = \frac{\partial V}{\partial t} + (V \cdot \nabla) V$	

### Diffusion and scaling during early embryonic pattern formation PNAS | December 20, 2005

Thomas Gregor\*<sup>†‡§</sup>, William Bialek<sup>\*†</sup>, Rob R. de Ruyter van Steveninck<sup>||</sup>, David W. Tank<sup>\*†‡</sup>, and Eric F. Wieschaus<sup>‡§</sup>



Courtesy of the National Academy of Sciences. Used with permission. Source: Gregor, Thomas et al. "Diffusion and scaling during early embryonic pattern formation." Proceedings of the National Academy of Sciences of the United States of America 102, no. 51 (2005): 18403-18407.



© source unknown. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/.

### Growth factors (e.g., IGF-1) and cytokines (e.g., TNFα) can bind to Extracellular Matrix molecules as well as cell receptors



#### **Cells live in a rich Extracellular Matrix**



#### (Dick Heinegård & Tore Saxne, Nature Revs. Rheumatology 2010)

© Wiley. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/. Source: Heinegård, Dick, and Tore Saxne. "The role of the cartilage matrix in osteoarthritis." Nature Reviews Rheumatology 7, no. 1 (2011): 50-56.

# Overview of the Matrisome—An Inventory of Extracellular Matrix Constituents and Functions

Richard O. Hynes and Alexandra Naba

Cold Spring Harbor 2012 PERSPECTIVES Perspectives in Biology

Howard Hughes Medical Institute, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

- Completion of the genome for many organisms allows a complete definition of extracellular matrix (ECM) proteins.
- In mammals this "core matrisome" comprises ~300 proteins.
- Also: there are many <u>ECM-binding growth factors</u>, ECM modifying enzymes, ECM modifying cytokines....

# Insulin-like Growth Factor-1 (IGF-1)

- Peptide Growth Factor:
  - Stimulates cellular biosynthesis;
  - Inhibits catabolic degradation of ECM
- Protein: 7.6 kDa (70 amino acids)
- "Folds" like Insulin in Aq. Solution
- pl ~ 8.4 ("basic" + charged @ pH 7)
- Found in: Nerve, Muscle, Connective, & Epithelial Tissues
  - Serum (50-200 ng/ml)
  - + Joint Fluid (20-50 ng/ml)
  - Tissue (1-10 ng/ml)....including BRAIN



Biochemistry, Vol. 40, No. 37, 2001 11025

Glu 3

FIGURE 1: Ribbon structure of IGF-1. The B-region (residues 3-28)

© American Chemical Society. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/. Source: Vajdos, Felix F. et al. "Crystal structure of human insulin-like growth factor-1: detergent binding inhibits binding protein interactions." Biochemistry 40, no. 37 (2001): 11022-11029.

# IGF-1 Transport: stimulate anabolic response

# (1) Through dense <u>tissue Extracellular Matrix</u> (ECM) of <u>collagens, proteoglycans, glycoproteins</u>... to cell



Original image © source unknown. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/.

# (2) <u>Binding Sites</u>: • Cell surface receptors (~10,000 / cell!) • IGF binding proteins





Original image © source unknown. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/.

Image: A product of the second state of the second stat

-1 IGFBP-2 IGFBP-3 IGFBP-4 IGFBP-5 IGFBP-6 Original image © source unknown. All rights reserved. This

content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/.



IGFBP-1

Original image © source unknown. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/.





# Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice PNAS 2009

Daniela Tropea<sup>a,1</sup>, Emanuela Giacometti<sup>b,1</sup>, Nathan R. Wilson<sup>a,1</sup>, Caroline Beard<sup>b</sup>, Cortina McCurry<sup>a</sup>, Dong Dong Fu<sup>b</sup>, Ruth Flannery<sup>b</sup>, Rudolf Jaenisch<sup>b,c,2</sup>, and Mriganka Sur<sup>a,2</sup>

<sup>a</sup>Picower Institute for Learning and Memory and Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139; <sup>b</sup>Whitehead Institute for Biomedical Research, Cambridge, MA 02142; and <sup>c</sup>Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139

 Rett patients express aberrantly high levels of IGFBP3, which inhibits IGF-1 signaling. Depressed IGF-1 signaling has indeed been implicated in autism spectrum disorder Phase 1 Trial: a small clinical trial at Mount Sinai School of Medicine in New York tested whether IGF-1 can treat some of the core symptoms of autism in children with Rett Syndrome.

.....Phase 1, 2013, completed: safety, **pharmacokinetics**, and preliminary assessment, .... "rh-IGF-1 is safe and well tolerated".....

Phase 2 trial in progress at Boston Children's Hospital: includes 30 children with Rett syndrome between the ages of 2 to 10 years old who are in "stable" stage of the disease. Outcome measures include: breathing and behavior

Phase 2 trial is still ongoing; if successful, it will be followed by a larger replication Phase 3 study....as required for FDA approval...

# **Experimental Setup: Transport**



### **IGFBP-3 Binding Slows entry of IGF-1 into Tissue!**



#### Prob Set 1, Prob 4 (But neglected binding of IGF-1 to anything)



Original image © source unknown. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/.

#### "Transient "

- non-steady
- non-equil.

$$\bar{c}_F(x,t) = c_1 \left(1 - \frac{x}{L}\right) - \frac{2Kc_1}{\pi} \sum_{n=1}^{\infty} \left[\frac{1}{n}\right] \sin\left(\frac{n\pi x}{L}\right) e^{-t/\tau_n}$$
(1.72)

$$\tau_n = \frac{L^2}{n^2 \pi^2 D_{\text{eff}}} \qquad \tau_1 = \frac{L^2}{\pi^2 D_{\text{eff}}} \tag{1.73}$$

### **Brain and Tissue Matrices**

for neurophysiology, anatomy, biochemical pharmacology

[ Brain and Tissue Matrices ] [ Stainless Steel Matrices ] [ Acrylic Brain Matrices ]

#### Slice thickness "L" ~ 200 – 500 $\mu m$



© Ted Pella, Inc. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/.

## Purify <sup>125</sup>I-IGF-1

#### Sephadex G50 Gel Filtration Chromatography





<sup>©</sup> Royal Pharmaceutical Society. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/.

# **Experimental Setup: Transport**



### **IGFBP-3 Binding Slows entry of IGF-1 into Tissue!**



slow reaction, or slow diffusion compared to reaction???

#### Prob Set 2, Prob 1



Original image © source unknown. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/.

#### "Transient "

- non-steady
- non-equil.

$$\bar{c}_F(x,t) = c_1 \left( 1 - \frac{x}{L} \right) - \frac{2Kc_1}{\pi} \sum_{n=1}^{\infty} \left( \frac{1}{n} \right) \sin\left( \frac{n\pi x}{L} \right) e^{-t/\tau_n}$$
(1.72)

$$\tau_n = \frac{L^2}{n^2 \pi^2 D_{\text{eff}}} \qquad \tau_1 = \frac{L^2}{\pi^2 D_{\text{eff}}} \tag{1.73}$$



(Bound IGF-1/ Free IGF-1) versus free IGF normalized to K<sub>d</sub>

20.430J / 2.795J / 6.561J / 10.539J Fields, Forces, and Flows in Biological Systems  $\mathsf{Fall}\ 2015$ 

For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.